Plant Name: Zanthoxylum schinifolium
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CNR1; CNR2; | |
| TSHR; | |
| GAA; ACHE; | |
| ALPL; FAAH; TDP1; TERT; AKR1B1; HSD17B10; ALOX15; ALDH1A1; APEX1; POLB; | |
| TRPA1; TRPV1; | |
| MAPK1; ATR; | |
| CA2; CA12; CA1; CA9; CA3; CA5B; CA7; CA5A; CA4; CA6; | |
| PPARA; PPARD; PPARG; | |
| KDM4E; | |
| TLR2; | |
| TP53; NFKB1; | |
| LMNA; FABP3; FABP5; FABP2; FABP4; MAPT; THPO; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | ATR | Serine-protein kinase ATR | Q13535 | CHEMBL5024 |
| Small molecule receptor (family A GPCR) | CNR1 | Cannabinoid CB1 receptor | P21554 | CHEMBL218 |
| Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.665E-13 | 1.325E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.120E-08 | 9.033E-06 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, PPARA, PPARD, PPARG, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.936E-08 | 1.318E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.936E-08 | 1.318E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.516E-08 | 3.225E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.069E-07 | 5.062E-05 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 4.827E-07 | 1.752E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 7.768E-07 | 2.563E-04 | CNR1, FABP3, PPARA, PPARG |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.740E-06 | 4.993E-04 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.934E-06 | 5.398E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 3.210E-06 | 8.525E-04 | AKR1B1, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PPARD |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.457E-06 | 9.070E-04 | ALOX15, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0090399; replicative senescence | 3.532E-06 | 9.156E-04 | ATR, TERT, TP53 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 6.567E-06 | 1.505E-03 | APEX1, POLB |
| BP | GO:0002376; immune system process | GO:0001774; microglial cell activation | 1.082E-05 | 2.265E-03 | MAPT, TLR2, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.124E-05 | 2.309E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.173E-05 | 2.386E-03 | CNR2, NFKB1, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0080134; regulation of response to stress | 1.376E-05 | 2.724E-03 | ATR, CNR1, CNR2, FABP4, LMNA, MAPK1, MAPT, NFKB1, PPARA, PPARD, PPARG, TERT, TLR2, TP53 |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 1.553E-05 | 3.047E-03 | AKR1B1, APEX1, NFKB1, PPARG, TP53, TSHR |
| BP | GO:0032501; multicellular organismal process | GO:0050968; detection of chemical stimulus involved in sensory perception of pain | 1.967E-05 | 3.481E-03 | TRPA1, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.967E-05 | 3.481E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.967E-05 | 3.481E-03 | CA2, CA7 |
| BP | GO:0032501; multicellular organismal process | GO:0050955; thermoception | 1.967E-05 | 3.481E-03 | TRPA1, TRPV1 |
| MF | GO:0005215; transporter activity | GO:0097603; temperature-gated ion channel activity | 1.967E-05 | 3.481E-03 | TRPA1, TRPV1 |
| MF | GO:0060089; molecular transducer activity | GO:0004949; cannabinoid receptor activity | 1.967E-05 | 3.481E-03 | CNR1, CNR2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.971E-05 | 3.481E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 2.036E-05 | 3.546E-03 | ACHE, AKR1B1, ALOX15, ALPL, ATR, CA2, CYP1A2, FABP5, GAA, LMNA, MAPK1, POLB, PPARA, PPARD, PPARG, SMN1, SMN2, THPO, TLR2, TP53, TSHR |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.100E-05 | 3.601E-03 | POLB, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.100E-05 | 3.601E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 2.700E-05 | 4.593E-03 | FABP3, PPARA, PPARD, PPARG |
| BP | GO:0032502; developmental process | GO:0007568; aging | 2.806E-05 | 4.665E-03 | APEX1, ATR, CNR1, POLB, TERT, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.787E-05 | 4.665E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0038171; cannabinoid signaling pathway | 3.927E-05 | 6.196E-03 | CNR1, CNR2 |
| BP | GO:0009987; cellular process | GO:0051289; protein homotetramerization | 3.999E-05 | 6.265E-03 | HSD17B10, TP53, TRPA1, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0009266; response to temperature stimulus | 4.223E-05 | 6.522E-03 | MAPT, PPARG, TP53, TRPA1, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 4.677E-05 | 7.172E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 5.988E-05 | 8.750E-03 | ALPL, PPARD, PPARG, TP53 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 6.534E-05 | 9.180E-03 | PPARA, PPARG |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 6.458E-05 | 9.180E-03 | MAPK1, MAPT, PPARA, PPARG, TP53 |
| BP | GO:0007610; behavior | GO:0007610; behavior | 6.762E-05 | 9.379E-03 | CNR1, GAA, MAPK1, MAPT, PPARA, TLR2, TP53, TRPV1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.537E-23 | 3.347E-19 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.251E-18 | 9.077E-15 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.203E-17 | 6.546E-14 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.006E-23 | 1.100E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 3.779E-10 | 2.967E-08 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 9.024E-09 | 4.723E-07 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.923E-07 | 3.110E-05 | CYP2C9; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 8.725E-06 | 2.740E-04 | CYP2C9; CYP2D6; ALOX15; MAPK1; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.091E-05 | 5.472E-04 | CYP2C9; CYP1A2; ALDH1A1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.313E-05 | 7.430E-04 | CYP2C9; CYP2D6; CYP1A2; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.236E-05 | 9.134E-04 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 5.132E-05 | 9.134E-04 | MAPK1; PPARG; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.126E-04 | 5.246E-03 | LMNA; MAPK1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.396E-04 | 5.246E-03 | MAPK1; PPARA; TP53; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.912E-04 | 5.246E-03 | MAPK1; NFKB1; PPARD |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 4.533E-04 | 5.246E-03 | POLB; TERT; TP53; NFKB1; ATR |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.835E-04 | 5.246E-03 | MAPK1; TP53; NFKB1; TLR2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 8.477E-04 | 7.005E-03 | CYP2C9; GAA; CYP1A2; ALOX15; ALDH1A1; AKR1B1; ALPL; CYP2C19; CYP3A4; HSD17B10 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.012E-04 | 5.246E-03 | CYP2C9; ALOX15; CYP2C19 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.022E-04 | 5.909E-03 | MAPK1; TP53; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 8.085E-04 | 7.005E-03 | MAPK1; TP53; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 8.085E-04 | 7.005E-03 | MAPK1; NFKB1; TLR2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.435E-03 | 1.093E-02 | MAPK1; TP53; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.532E-03 | 1.093E-02 | MAPK1; PPARA; NFKB1; TSHR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.707E-03 | 1.117E-02 | POLB; MAPK1; TP53; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.679E-03 | 1.117E-02 | PPARG; TP53; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.058E-03 | 1.600E-02 | MAPK1; PPARG; TP53; NFKB1; PPARD |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 2.062E-03 | 1.295E-02 | FAAH; CNR1; MAPK1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.367E-03 | 1.376E-02 | MAPK1; NFKB1; TLR2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.242E-03 | 1.354E-02 | MAPK1; NFKB1; TLR2 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 3.753E-03 | 1.733E-02 | MAPK1; MAPT; TP53; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.207E-03 | 1.600E-02 | MAPK1; NFKB1; TLR2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.362E-03 | 1.600E-02 | MAPK1; TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.362E-03 | 1.600E-02 | MAPK1; TP53; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 4.392E-03 | 1.970E-02 | MAPK1; PPARG; NFKB1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 5.030E-03 | 2.078E-02 | CNR2; CNR1; TRPV1; TSHR |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 4.774E-03 | 2.026E-02 | TP53; NFKB1; TLR2 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 8.546E-03 | 3.160E-02 | MAPK1; MAPT; HSD17B10 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.032E-02 | 3.373E-02 | MAPK1; TP53; NFKB1; TLR2 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.000E-02 | 3.373E-02 | MAPK1; NFKB1; TLR2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.031E-02 | 3.373E-02 | PPARG; TP53; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.110E-02 | 3.414E-02 | TP53; NFKB1; TLR2 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.423E-02 | 3.641E-02 | MAPK1; TP53; TLR2 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 7.500E-03 | 3.019E-02 | MAPK1; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 8.655E-03 | 3.160E-02 | FABP4; TSHR |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 8.655E-03 | 3.160E-02 | MAPK1; TP53 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 8.359E-03 | 3.160E-02 | NFKB1; TLR2 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.499E-03 | 1.093E-02 | CA2; CA4 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.720E-03 | 2.026E-02 | MAPK1; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.053E-02 | 3.373E-02 | MAPK1; TP53 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.152E-02 | 3.414E-02 | MAPK1; TP53 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 8.955E-03 | 3.195E-02 | MAPK1; NFKB1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.548E-03 | 1.429E-02 | GAA; AKR1B1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.221E-02 | 3.550E-02 | MAPK1; TP53 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.152E-02 | 3.414E-02 | NFKB1; TLR2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 9.260E-03 | 3.231E-02 | CYP1A2; CYP3A4 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.364E-02 | 3.629E-02 | MAPK1; TP53 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.400E-02 | 3.641E-02 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.438E-02 | 3.641E-02 | MAPK1; NFKB1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.327E-02 | 3.629E-02 | PPARA; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.959E-02 | 4.731E-02 | TP53; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.152E-02 | 3.414E-02 | MAPK1; NFKB1 |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.292E-02 | 3.621E-02 | TP53; ATR |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.364E-02 | 3.629E-02 | CA2; CYP3A4 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.959E-02 | 4.731E-02 | MAPK1; NFKB1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 3.078E-03 | 1.600E-02 | POLB; APEX1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.513E-02 | 3.771E-02 | MAPK1; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.244E-02 | 3.551E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | CNR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; MAPT; PPARG; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TRPV1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | CNR1; PPARG |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; PPARG |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | CNR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; TERT |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | CNR1; NFKB1; PPARD; PPARG; PPARG |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2; TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chemotherapy-induced nausea | R11 | CNR1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | CNR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | CNR1; PPARD; MAPT |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | ATR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; CA9; MAPK1; TLR2; ATR |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| NA: NA | Esophagus sensitivity | NA | TRPV1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | TP53; CA1; CA9; MAPK1; NFKB1; TLR2; ACHE; ATR |
| NA: NA | Dyslipidemia | NA | PPARD |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; CNR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; TERT |
| NA: NA | Edema | NA | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CNR1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | CNR1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | CNR1; CNR1; CNR1; CNR1; CNR1; CNR1; PPARD; PPARD; PPARG |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; TRPV1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; TERT |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | CNR1; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | TRPV1; CNR2 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR1; TRPV1; CNR2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | CNR1; CNR1; CNR1; AKR1B1; PPARG |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | CNR1; TRPV1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CNR1; CYP2D6 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH; CNR2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | CNR2; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR1; FAAH; TRPA1; ACHE; TRPV1; TRPV1; CNR2 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; TRPV1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | CNR1; TERT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CNR2 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | CNR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CNR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; FAAH; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anorexia | F50.0-F50.1 | CNR1 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |